Medical Pharmacology Question Bank: ANS Cholinergic Pharmacology — Module 3 | Tier 4 — Extended Clinical Cases
Chapter 6: Cholinergic Pharmacology — Module 3: Nicotinic Pharmacology — NMJ, Ganglionic, and CNS Drugs
Tier 4 — Clinical Case Reasoning
CASE 1: RSI AND NEUROMUSCULAR BLOCKADE IN MORBID OBESITY
A 52-year-old man with morbid obesity (weight 148 kg, BMI 52 kg/m2), obstructive sleep apnea (OSA) on home CPAP (continuous positive airway pressure), and type 2 diabetes presents with aspiration pneumonia following witnessed vomiting. He is in moderate respiratory distress, SpO2 88% on 15 L/min non-rebreather, respiratory rate 28, tiring. Neck circumference 52 cm, Mallampati III. No drug allergies, no prior anesthesia problems. Potassium 3.7 mEq/L, creatinine 1.1 mg/dL. Emergency RSI is indicated.
1. Before selecting the neuromuscular blocking agent, the physician considers how weight-based dosing should be determined for succinylcholine and rocuronium in morbid obesity. Which of the following correctly describes dosing principles for neuromuscular blocking agents in morbid obesity?
ANSWER: D
Rationale:
Dosing of neuromuscular blocking agents in morbid obesity requires understanding which pharmacokinetic parameters are altered by excess adipose tissue. Succinylcholine is correctly dosed on total body weight. Butyrylcholinesterase activity — the sole determinant of succinylcholine hydrolysis rate and duration — scales with total body mass in obese patients; heavier patients have proportionally higher plasma BChE activity. Dosing succinylcholine on ideal body weight risks inadequate block depth or shorter duration than expected. The standard RSI dose of 1.5 mg/kg TBW is appropriate; for this 148 kg patient that calculates to approximately 220 mg. Rocuronium's volume of distribution does not increase proportionally with excess fat mass because adipose tissue is poorly vascularized and rocuronium distributes primarily into well-perfused lean body mass. Dosing rocuronium on total body weight produces a disproportionately high dose relative to the pharmacologically relevant distribution volume, resulting in substantially prolonged duration — potentially 90 minutes or longer — without meaningfully faster onset. Rocuronium for RSI in morbid obesity should be dosed on ideal body weight at 1.2 mg/kg IBW. For a 180 cm male, IBW is approximately 79 kg, giving a rocuronium RSI dose of approximately 95 mg.
2. The physician selects succinylcholine for RSI given the Mallampati III airway. The team must optimize pre-oxygenation, recognizing that morbid obesity alters respiratory physiology in ways relevant to RSI safety. Which of the following most accurately describes the physiological basis for modified pre-oxygenation in morbid obesity and its relationship to the choice of succinylcholine?
ANSWER: A
Rationale:
Morbid obesity substantially reduces functional residual capacity. Cephalad diaphragmatic displacement by abdominal and thoracic fat, increased chest wall weight limiting passive lung expansion, and airway closure at higher lung volumes may reduce FRC by 50% or more compared with lean individuals in the supine position. Because FRC constitutes the oxygen reservoir during apnea, a reduced FRC means critical desaturation after apnea onset occurs far more rapidly — safe apnea time in an optimally pre-oxygenated morbidly obese patient may be as short as 2–3 minutes compared with 8–10 minutes in a healthy lean adult. This directly establishes the clinical relevance of succinylcholine's short duration. If the first intubation attempt fails and mask ventilation proves difficult, spontaneous ventilation returning within 8–12 minutes with succinylcholine provides a critical safety fallback. With rocuronium at RSI doses, this same window requires immediately prepared and administered sugammadex 16 mg/kg. When sugammadex availability is confirmed, rocuronium is equally safe; when uncertain, succinylcholine's spontaneous offset is the more reliable backup. Pre-oxygenation in the ramped position — head elevated 20–30 degrees — combined with 8 maximal vital capacity breaths or 3 minutes at 100% FiO2 maximizes the initial oxygen reservoir and extends safe apnea time by approximately 1–2 minutes. Option E is partially correct about FRC and technique but incorrectly implies NMB choice is unrelated to the rescue planning calculation.
3. Intubation is successful on the first attempt. The patient proceeds to emergent laparoscopic washout planned for 3 hours. Rocuronium is selected for maintenance blockade. The anesthesiologist must determine the monitoring and reversal strategy for this high-pulmonary-risk patient. Which of the following best describes the optimal approach?
ANSWER: C
Rationale:
This patient has multiple converging risk factors making residual neuromuscular blockade particularly consequential. Morbid obesity reduces FRC and increases work of breathing such that minor residual NMB has disproportionate ventilatory impact. Obstructive sleep apnea indicates baseline pharyngeal muscle tone impairment that is further worsened by any residual NMB. Aspiration-related pulmonary compromise further reduces ventilatory reserve. Together these factors place him among the highest-risk patients for PACU respiratory complications from residual NMB. Contemporary guidelines recommend quantitative neuromuscular monitoring — confirming TOF ratio of at least 0.9 with an objective device before extubation — as the standard of care regardless of body habitus. Clinical assessment tools including head lift, grip strength, and tidal volume are unreliable and cannot detect TOF ratios between 0.4 and 0.9 in most patients. Neostigmine administered at TOF count below 4 with visible fade produces unreliable reversal and is a recognized cause of PACU respiratory complications after rocuronium. Sugammadex is the preferred reversal agent in this patient: it reliably achieves TOF ratio of at least 0.9 regardless of block depth, eliminates the risk of incomplete reversal, and requires no anticholinergic co-administration. Option D creates a clinically unfounded distinction between bolus and infusion dosing.
4. At the conclusion of the 3-hour procedure, quantitative TOF monitoring shows a TOF count of 4 with a TOF ratio of 0.62. The anesthesiologist administers sugammadex rather than neostigmine. Which of the following most accurately justifies this decision and identifies the appropriate dose?
ANSWER: E
Rationale:
At TOF ratio 0.62 with TOF count 4, the block is in the moderate residual range — below the threshold of 0.9 required for safe extubation. Residual blockade at this level carries meaningful risk of pharyngeal dysfunction, aspiration, and upper airway obstruction that is substantially amplified by this patient's obesity, OSA, and aspiration-related pulmonary compromise. Neostigmine is pharmacologically viable at TOF ratio 0.62 with TOF count 4 because competitive acetylcholine accumulation can provide reversal in this range. However, neostigmine has a well-established ceiling effect above approximately 0.04–0.07 mg/kg; additional dose does not hasten reversal and increases muscarinic toxicity. Speed of reversal from TOF ratio 0.62 to greater than 0.9 with neostigmine is variable, can take 10–20 minutes, and incomplete reversal leaving TOF ratio between 0.7 and 0.9 is a recognized outcome. In this patient, any residual NMB has disproportionate respiratory consequences. Sugammadex 2 mg/kg is the appropriate dose for moderate blockade — defined as TOF count of at least 2 — with aminosteroidal NMBs, and predictably achieves TOF ratio of at least 0.9 within approximately 3 minutes. This reliability and the elimination of muscarinic side effects requiring anticholinergic co-administration make sugammadex the preferred choice in this high-risk patient. Quantitative confirmation of TOF ratio at least 0.9 must be documented before extubation regardless of which reversal agent is used.
CASE 2: MALIGNANT HYPERTHERMIA CRISIS
A 16-year-old male with no known medical history undergoes elective open reduction and internal fixation of a mid-shaft femur fracture. Preoperative vital signs are normal. Anesthesia is induced with propofol 200 mg and succinylcholine 100 mg, and maintained with sevoflurane 2% in oxygen-air. Approximately 20 minutes into the procedure, end-tidal CO2 has risen from 38 to 68 mmHg despite increased minute ventilation. Progressive jaw and extremity rigidity is noted. Temperature is 38.1 degrees C, rising from 36.9 degrees C at induction. Heart rate 118 bpm. ABG: pH 7.22, PaCO2 74, HCO3 17, lactate 5.4 mmol/L, potassium 5.8 mEq/L.
5. The anesthesiologist recognizes a probable MH crisis. The team asks whether any alternative diagnosis should be seriously considered before committing to the MH response protocol. Which of the following most accurately characterizes the diagnosis and the key features confirming MH?
ANSWER: B
Rationale:
The clinical presentation is a textbook MH crisis, and the specific constellation of findings is sufficiently characteristic that MH must be treated immediately without waiting for confirmatory testing. The following features together are diagnostic: rapidly rising end-tidal CO2 that outpaces increased minute ventilation, reflecting massive CO2 production from uncontrolled skeletal muscle metabolism and representing the earliest and most sensitive sign of MH; progressive generalized muscle rigidity from uncontrolled calcium-driven actin-myosin cross-bridge cycling; hyperthermia with rapid temperature rise reflecting the thermodynamic output of uncontrolled metabolism; mixed respiratory and metabolic acidosis with elevated lactate from simultaneous CO2 accumulation and anaerobic glycolysis; hyperkalemia from massive potassium efflux from depolarized muscle; and dual triggering agent exposure — both a volatile halogenated agent (sevoflurane) and succinylcholine — in a previously healthy young patient with no prior anesthetic history. The clinical diagnosis of MH does not require a caffeine-halothane contracture test or in-vitro contracture test. These tests — performed on fresh muscle biopsy specimens at specialized MH centers — are used for susceptibility evaluation in patients who have survived an MH event and their first-degree relatives, to identify carriers of MH susceptibility mutations before future anesthetic exposures. They have no role as a real-time diagnostic tool during a crisis and treatment cannot be delayed to obtain them. No alternative diagnosis produces this specific intraoperative constellation. Septic shock from bacteremia does not cause acute muscle rigidity or the acute-onset hypercarbia trajectory described. Pheochromocytoma crisis can produce fever and tachycardia but does not cause muscle rigidity or this EtCO2 pattern; additionally, the absence of known family history of anesthesia problems does not reduce the likelihood of MH, since most events occur in patients with no prior family exposure. Pseudocholinesterase deficiency causes prolonged apnea but not rigidity, fever, or metabolic acidosis. Propofol does not trigger neuroleptic malignant syndrome.
6. The MH diagnosis is confirmed clinically and the MH response protocol is activated. The anesthesia technician asks which actions should be prioritized in the first 2 minutes. Which of the following correctly prioritizes the immediate pharmacological and non-pharmacological interventions?
ANSWER: D
Rationale:
MH is a rapidly progressive, life-threatening emergency in which every minute of continued triggering agent exposure worsens the intracellular calcium crisis driving the syndrome. The MH treatment protocol prioritizes actions in the following sequence, with the first several steps occurring simultaneously. Immediate simultaneous actions include: calling for maximal help (additional anesthesiologists, surgeons, nurses, pharmacy), activating the institution's MH protocol, and discontinuing all volatile halogenated anesthetics (sevoflurane) and succinylcholine infusion if running, followed immediately by switching to total IV anesthesia with propofol to maintain surgical anesthesia — propofol is not a triggering agent and is safe in MH-susceptible individuals. Dantrolene is the only specific treatment for MH and must be prepared and administered as rapidly as possible. The initial dose is 2.5 mg/kg IV bolus (not a reduced dose — 0.5 or 1 mg/kg is insufficient for an established crisis), administered as rapidly as possible and repeated every 5 minutes to a maximum of 10 mg/kg, or until the clinical signs of MH — rising EtCO2, rigidity, hyperthermia — begin to resolve. Higher cumulative doses are sometimes required in severe cases. Simultaneously, active surface cooling (ice packs, cooling blankets, cold IV fluids), arterial line placement for continuous blood pressure monitoring and serial ABGs, IV access optimization, hyperventilation to wash out CO2, and treatment of hyperkalemia (calcium gluconate or chloride for cardiac protection, sodium bicarbonate, glucose-insulin, and consideration of dialysis in severe cases) should proceed in parallel with dantrolene administration. The MH hotline provides expert real-time guidance for the treating team. Option C is dangerously incorrect — completing surgery before treating MH is contraindicated; the procedure must be stopped or abbreviated as rapidly as possible.
7. Dantrolene has been administered and the MH crisis is beginning to respond, with EtCO2 declining and rigidity lessening. A medical student on the rotation asks the attending anesthesiologist to explain exactly how dantrolene works at the molecular level to stop the MH crisis. Which of the following most accurately describes dantrolene's mechanism of action in MH?
ANSWER: A
Rationale:
Dantrolene acts directly on the ryanodine receptor type 1, the calcium release channel located in the membrane of the sarcoplasmic reticulum in skeletal muscle. RYR1 is a massive homotetrameric protein that is the principal calcium release channel responsible for the calcium-induced calcium release that amplifies and sustains the calcium transient during normal excitation-contraction coupling. In MH-susceptible individuals, mutant RYR1 channels have an abnormally low threshold for activation by volatile anesthetics and succinylcholine, and once activated undergo sustained, unregulated opening rather than the brief, controlled release seen in normal muscle. Dantrolene binds to a specific site on the cytoplasmic domain of RYR1, likely involving interactions with the FKBP12 binding domain — a region of the receptor involved in regulatory protein interactions that modulate channel gating. By binding at this site, dantrolene stabilizes the closed state of the channel and reduces its probability of pathological opening in response to triggering agent stimulation or the calcium-induced calcium release cycle that perpetuates the crisis. This action does not block normal action potential generation, does not interfere with neuromuscular junction nicotinic receptor function, and does not chelate calcium ions directly. The net result is suppression of the intracellular calcium surge that drives uncontrolled actin-myosin cycling, thermogenesis, and metabolic acidosis.
8. The MH crisis is successfully aborted after a total dantrolene dose of 7 mg/kg. The patient is stable, sedated, and mechanically ventilated in the ICU. The attending anesthesiologist must plan ongoing post-crisis management and counseling for the patient and his family. Which of the following most accurately describes the post-crisis pharmacological management and the appropriate genetic and family counseling steps?
ANSWER: C
Rationale:
Post-crisis management of MH requires continued vigilance because MH recrudescence — re-emergence of the hypermetabolic crisis after apparent initial control — occurs in approximately 20–25% of successfully treated patients, typically within the first 24–48 hours. The most commonly recommended regimen to prevent recrudescence is dantrolene 1 mg/kg IV every 4–6 hours for 24–48 hours, or a continuous infusion of 0.25 mg/kg/hour, with the total duration guided by the clinical trajectory. Patients should be monitored continuously in the ICU during this period, with serial temperature, EtCO2 (if still ventilated), CPK, potassium, renal function, urine output, and coagulation studies. Dantrolene hepatotoxicity is a real but dose-dependent and time-dependent concern — significant hepatotoxicity is uncommon at the doses and durations used for MH treatment compared with the much higher chronic doses historically used for spasticity. The risk of stopping dantrolene prematurely is recrudescence, which can be fatal. Regarding genetic counseling and family referral: MH susceptibility is an autosomal dominant condition with variable penetrance. Approximately 70% of MH-susceptible families carry identifiable mutations in RYR1, with a smaller proportion carrying CACNA1S mutations or mutations in other genes. After an MH event, the following steps are recommended: referral of the patient and all first-degree relatives to an MH-accredited center for susceptibility testing — either CHCT in North America or IVCT in Europe — which remains the gold standard diagnostic test; genetic testing for known MH causative mutations, which if positive can spare relatives from muscle biopsy; registration with an MH susceptibility registry; and provision of written documentation that the patient carries MH susceptibility to be presented at all future healthcare encounters. All future anesthetic management must avoid volatile halogenated anesthetics and succinylcholine; total IV anesthesia with propofol is safe and recommended. Nitrous oxide, non-depolarizing NMBs, and local anesthetics are not triggering agents and are safe.
CASE 3: SMOKING CESSATION PHARMACOTHERAPY
A 49-year-old woman with a 30 pack-year smoking history presents requesting help to quit. She has hypertension controlled on amlodipine, mild COPD (GOLD Stage 1), and a body mass index of 29 kg/m2. She has made three prior quit attempts: the first using nicotine patch alone lasted 6 weeks before relapse triggered by a stressful work event; the second using nicotine gum alone lasted 3 weeks; and the third using the patch again lasted 8 weeks before relapse at a social gathering where others were smoking. She reports persistent cravings throughout all quit attempts and describes both environmental cue-triggered and stress-triggered urges as equally problematic. She is highly motivated and specifically asks what the most effective pharmacological strategy is. She takes no antidepressants and has no psychiatric history. She drinks one glass of wine occasionally and takes no other medications.
9. The physician begins by reviewing the patient's prior NRT experience to understand why monotherapy with patch or gum failed, and whether combination NRT is likely to offer meaningful benefit over her prior attempts. Which of the following most accurately explains the pharmacological rationale for combination NRT over monotherapy and its expected efficacy compared with prior single-agent NRT in this patient?
ANSWER: C
Rationale:
Combination NRT — using a long-acting transdermal patch to maintain stable background nicotine levels and suppress baseline withdrawal symptoms, paired with a short-acting rescue form (gum, lozenge, inhaler, or nasal spray) for on-demand management of breakthrough cravings — consistently produces higher sustained abstinence rates than patch monotherapy across multiple randomized trials and meta-analyses. The pharmacological rationale is straightforward: the patch manages trough-level withdrawal dysphoria and baseline craving, while the rescue form provides rapid nicotinization to blunt acute urges triggered by stress or environmental cues. However, even optimally used combination NRT has a fundamental pharmacological limitation that is directly relevant to this patient's relapse history. All NRT products are full agonists at nicotinic receptors — they provide replacement nicotinic stimulation but do not block the reinforcing effects of additionally smoked cigarettes. When this patient smoked at a stressful work event or a social gathering, the tobacco-derived nicotine delivered a full agonist response at (alpha-4)2(beta-2)3 receptors in the mesolimbic pathway on top of already-occupied receptors, producing a dopaminergic reward that reinforced relapse. NRT cannot prevent this because it has no blocking component. This is precisely the mechanistic gap that varenicline fills. As a partial agonist at (alpha-4)2(beta-2)3 receptors, varenicline simultaneously provides enough receptor activation to suppress withdrawal and craving while occupying the receptor in a way that blunts the full rewarding surge when tobacco nicotine is also present. For a patient with three prior NRT failures characterized by persistent craving and cue- and stress-triggered relapse, varenicline addresses the neurobiology of relapse in a way that NRT cannot. This patient should be offered varenicline as the primary agent, with or without adjunctive NRT. Option B is partially correct about combination NRT and the recommendation for varenicline but is too permissive about combination NRT as a primary option for this patient.
10. The physician decides to prescribe varenicline as the primary pharmacotherapy. The patient asks how it works and how it differs from the nicotine patch she has used before. Which of the following most accurately explains varenicline's mechanism and its pharmacological advantages over nicotine replacement therapy in this patient?
ANSWER: A
Rationale:
Varenicline is a selective partial agonist at (alpha-4)2(beta-2)3 nicotinic receptors, which are the predominant high-affinity nicotine-binding sites in the brain and the primary mediators of nicotine's rewarding and addictive properties. These receptors are located on dopaminergic neurons in the ventral tegmental area whose axons project to the nucleus accumbens, and their activation triggers dopamine release in the nucleus accumbens — the neurobiological substrate of reward, reinforcement, and addiction. As a partial agonist, varenicline occupies (alpha-4)2(beta-2)3 receptors and produces activation at approximately 40–60% of nicotine's maximal efficacy. This level of receptor stimulation is sufficient to maintain dopamine tone in the nucleus accumbens above the dysphoric withdrawal baseline, thereby reducing craving, irritability, anxiety, and the motivational drive to smoke. Critically, because a partial agonist by definition cannot produce the same maximal receptor activation as a full agonist regardless of concentration, varenicline's receptor occupancy establishes a ceiling on dopaminergic reward — when the patient does smoke, tobacco-derived nicotine cannot drive receptor activation significantly above the varenicline-occupied level, and the expected full rewarding surge is blunted. This removes a key reinforcer of relapse. In direct comparison with NRT, this patient can understand the difference as follows: the nicotine patch provided replacement stimulation to prevent withdrawal but left the reward pathway fully available to tobacco-derived nicotine, meaning that smoking delivered a complete reward that reinforced relapse. Varenicline provides partial background stimulation that prevents withdrawal and simultaneously limits the reward available from smoking, attacking both the push (withdrawal) and the pull (reward) of addiction simultaneously.
11. The patient asks about bupropion as an alternative, having heard about it from a friend. The physician explains how bupropion works and why it is or is not the preferred option for her. Which of the following most accurately describes bupropion's mechanism of action for smoking cessation and its pharmacological comparison with varenicline in this patient?
ANSWER: E
Rationale:
Bupropion's mechanism of action in smoking cessation involves two pharmacological properties. The primary established mechanism is inhibition of dopamine and norepinephrine reuptake transporters in mesolimbic and prefrontal circuits, increasing the synaptic availability of these monoamines. This tonic increase in dopamine tone is thought to partially compensate for the hypodopaminergic state of nicotine withdrawal, reducing the motivational drive to smoke and blunting some withdrawal symptoms including low mood, irritability, and anhedonia. The secondary mechanism is weak, non-competitive antagonism at neuronal nicotinic acetylcholine receptors — bupropion blocks the ion channel pore in a use-dependent fashion, reducing nicotinic transmission somewhat. This is distinct from varenicline's partial agonist mechanism and does not provide the competitive receptor occupancy that blunts tobacco nicotine reward. Because bupropion has no meaningful partial agonist activity at (alpha-4)2(beta-2)3 receptors, it cannot occupy these receptors in a way that limits the rewarding response to breakthrough smoking. A patient who smokes while on bupropion receives the full dopaminergic reward from tobacco-derived nicotine — the reinforcement of relapse is not attenuated. This is the key pharmacological distinction from varenicline. Meta-analyses of randomized controlled trials consistently demonstrate that varenicline produces sustained abstinence rates approximately 1.5–2 times higher than bupropion. In a patient with three NRT failures and persistent cue- and stress-triggered relapse, the superior efficacy of varenicline makes it the preferred agent. Practical considerations: bupropion is initiated 1–2 weeks before the quit date at 150 mg once daily for 3 days then 150 mg twice daily. It lowers the seizure threshold — a consideration in patients on medications that share this effect. There is no clinically significant interaction between bupropion and amlodipine. Bupropion is a CYP2D6 inhibitor and can elevate levels of drugs metabolized by CYP2D6, but amlodipine is metabolized primarily by CYP3A4, not CYP2D6.
12. Varenicline is prescribed, and the patient successfully quits smoking after 4 weeks. At the 12-week follow-up visit she remains abstinent but describes persistent background craving and reports that she still finds social situations where others smoke extremely difficult to navigate. She asks whether there is anything else that can be offered to improve her chances of long-term success. Which of the following best describes the pharmacological options for optimizing long-term abstinence in a patient who has responded to varenicline but continues to experience persistent background craving and cue-triggered urges at 12 weeks?
ANSWER: B
Rationale:
Extended varenicline therapy beyond the initial 12-week course is both evidence-based and guideline-supported. The EAGLES (Evaluating Adverse Events in a Global Smoking Cessation Study) trial and multiple other randomized trials have demonstrated that extending varenicline treatment to 24 weeks — an additional 12 weeks of continued therapy — significantly improves long-term sustained abstinence rates compared with stopping at 12 weeks, with number-needed-to-treat values that are clinically meaningful. This is particularly relevant for patients with persistent craving at 12 weeks, as their neurobiological addiction profile suggests that shorter treatment duration is unlikely to be sufficient for sustained remission. The addition of adjunctive short-acting NRT to varenicline in patients with persistent breakthrough craving is supported by evidence from randomized trials and represents a rational pharmacological combination. Varenicline's partial agonism provides sustained background (alpha-4)2(beta-2)3 receptor activation that suppresses withdrawal and blunts tobacco reward; the short-acting NRT rescue form (gum or lozenge) provides on-demand supplemental nicotinic stimulation during acute cue-triggered urges that may transiently exceed varenicline's partial agonist ceiling effect. The combination is not contraindicated — the additional nicotinic input from NRT does not produce the full addictive reward cycle because the receptor is already partially occupied and the NRT dose is modest. The combination has been shown to improve abstinence in patients with persistent craving beyond what either agent achieves alone. Cytisine is a naturally occurring plant alkaloid (from Laburnum anagyroides) that also acts as a partial agonist at (alpha-4)2(beta-2)3 receptors, with a mechanism similar to varenicline. It has demonstrated efficacy superior to placebo and comparable to or exceeding NRT in randomized trials, and at substantially lower cost than varenicline. However, the claim in option D that cytisine has demonstrated superiority over varenicline in head-to-head trials and is now the preferred first-line agent in all guidelines is not accurate as of current evidence — direct head-to-head trial data with varenicline are limited and no major guideline currently positions cytisine as universally superior to varenicline.
CASE 4: LEMS (Lambert-Eaton Myasthenic Syndrome) WITH SMALL-CELL LUNG CANCER
A 63-year-old male former smoker with a 45 pack-year history presents with a 5-month progressive history of proximal lower extremity weakness, most prominent when rising from a chair or climbing stairs, that improves noticeably after 5–10 minutes of sustained activity. He also reports dry mouth for the past 4 months, constipation, and erectile dysfunction. He denies diplopia, ptosis, or dysphagia. Neurological examination shows proximal lower extremity weakness graded 3/5 bilaterally, preserved distal strength and facial muscles, depressed patellar reflexes that augment to normal amplitude after 10 seconds of maximal voluntary quadriceps contraction, and mild orthostatic hypotension. Chest CT reveals a 3.4 cm right hilar mass with mediastinal lymphadenopathy. Bronchoscopic biopsy confirms small-cell lung cancer. Serum antibodies against P/Q-type voltage-gated calcium channels are detected at high titer. Repetitive nerve stimulation at 3 Hz shows a 15% decrement; at 50 Hz shows a 380% increment in compound muscle action potential amplitude.
13. The neurology team is asked to characterize this patient's neuromuscular syndrome and explain why it should be distinguished from myasthenia gravis, which may be considered in the differential. Which of the following most accurately differentiates this patient's syndrome from myasthenia gravis on clinical, electrophysiological, and serological grounds?
ANSWER: D
Rationale:
This patient has classic paraneoplastic Lambert-Eaton myasthenic syndrome, and the distinction from myasthenia gravis is supported by every element of the presentation. LEMS is a presynaptic disorder: autoantibodies against P/Q-type (Cav2.1) voltage-gated calcium channels in the presynaptic terminal reduce calcium entry per action potential, impairing acetylcholine vesicle exocytosis and reducing the quantal content of each end-plate potential. This is fundamentally different from MG, which is a postsynaptic disorder in which antibodies against AChR (85–90% of cases) or MuSK (5–8%) or LRP4 (lipoprotein receptor-related protein 4) destroy or functionally impair postsynaptic receptors. The clinical differences are diagnostically reliable. Exercise-induced improvement is the hallmark of LEMS, explained mechanistically by progressive intracellular calcium accumulation during repetitive nerve firing, which facilitates acetylcholine release. In MG, exercise characteristically worsens weakness because it depletes the readily releasable vesicle pool against a background of reduced postsynaptic receptor density. Autonomic involvement — dry mouth, constipation, erectile dysfunction, and orthostatic hypotension — is present in approximately 80% of LEMS patients and reflects VGCC (voltage-gated calcium channel) autoantibody-mediated impairment of autonomic nerve terminal calcium entry; autonomic features are not characteristic of MG. Reflexes that augment after voluntary contraction are the bedside correlate of the incremental EMG response and are distinctive for LEMS. Extraocular and bulbar muscles are prominently affected early in MG (ptosis, diplopia, dysphagia) but are typically spared or mildly affected in LEMS. Electrophysiologically, the 15% decrement at 3 Hz combined with the 380% increment at 50 Hz is the defining dual signature of LEMS. MG produces a larger decrement (typically 10–30%) at low-frequency stimulation (3 Hz) with no significant increment at high frequency. The P/Q-type VGCC antibodies detected at high titer confirm the serological diagnosis.
14. The neurology fellow asks the attending to explain in detail why weakness improves with exercise in LEMS and worsens with exercise in myasthenia gravis, using the molecular pathophysiology of each condition. Which of the following most accurately explains the opposite exercise responses in LEMS and MG at the molecular level?
ANSWER: A
Rationale:
The opposite exercise responses in LEMS and MG are elegant reflections of their respective presynaptic and postsynaptic pathophysiology. In LEMS, the fundamental deficit is reduced calcium entry per action potential. Normally, an action potential in the motor nerve terminal opens P/Q-type VGCCs, and the resulting calcium influx triggers fusion of the readily releasable pool of acetylcholine vesicles with the presynaptic membrane, releasing acetylcholine into the synapse. With VGCC autoantibodies reducing functional channel number, each action potential produces less calcium influx, fewer vesicle fusion events, and a smaller quantal content — meaning fewer acetylcholine molecules are released per stimulus. At low stimulation frequencies and at rest, this deficit is sufficient to prevent reliable end-plate potential generation in many fibers, producing weakness. During repetitive firing at exercise rates, however, the inter-stimulus interval (20–50 ms at physiological rates) is shorter than the time constant of calcium removal from the presynaptic terminal by SERCA pumps and NCX exchangers. Residual calcium from each action potential therefore adds to the calcium from the next, raising the pre-stimulus calcium concentration progressively with each successive action potential. This increasing residual calcium enhances vesicle fusion probability, increasing quantal content of release and progressively recruiting more end-plate potentials above threshold — the physiological basis of facilitation and clinical improvement with exercise. In MG, the problem is postsynaptic. AChR antibodies reduce functional receptor density at the end-plate, narrowing the safety factor for neuromuscular transmission — the ratio of actual end-plate potential amplitude to the threshold required for muscle action potential generation. At rest, the reduced receptor density may still permit transmission because the margin between actual EPP (end-plate potential) amplitude and threshold, while narrowed, is sufficient in many fibers. With repeated stimulation, the presynaptic terminal progressively depletes the readily releasable vesicle pool; unlike the resting pool, which is replenished over seconds to minutes, the immediately available pool drains faster than it can be replenished during rapid firing. Each successive stimulus therefore releases less acetylcholine, generating a smaller EPP — and against a background of already-reduced receptor density, progressive EPP decrement causes more and more fibers to fall below threshold for action potential generation, producing incremental weakness and the decremental EMG pattern.
15. The neurology team initiates amifampridine (3,4-diaminopyridine) to improve this patient's neuromuscular strength while the oncology team prepares to begin chemotherapy for the SCLC (small cell lung cancer). Which of the following most accurately describes amifampridine's mechanism of action and why it specifically benefits LEMS but would not be expected to benefit myasthenia gravis?
ANSWER: C
Rationale:
Amifampridine (3,4-diaminopyridine [DAP — a potassium channel blocker], or 3,4-DAP) is the primary pharmacological treatment for LEMS and received FDA approval in 2018. Its mechanism is blockade of voltage-gated potassium channels (primarily Kv1 family channels) in the presynaptic motor nerve terminal membrane. Under normal circumstances, following an action potential, the rapid inactivation of sodium channels and the opening of voltage-gated potassium channels drives membrane repolarization, terminating the action potential and limiting the duration of VGCC opening and calcium entry. When amifampridine blocks these potassium channels, the outward potassium current that normally drives repolarization is impaired, prolonging the action potential plateau phase. This extended depolarization maintains VGCCs in the open state for a longer period per stimulus, increasing the total calcium influx per action potential. In LEMS, where the number of functional VGCCs is already reduced by autoantibodies, this prolongation of calcium entry time directly compensates for the reduced channel density by extracting more calcium through each surviving channel per action potential. The result is increased acetylcholine vesicle fusion and increased quantal content of release, partially restoring end-plate potential amplitude and NMJ transmission reliability. This mechanism explains why amifampridine specifically benefits LEMS: the deficit is presynaptic calcium entry, and amifampridine directly addresses this by prolonging the calcium entry window. In MG, the presynaptic release mechanism is structurally intact — there is no deficit in calcium entry or ACh release. The problem is postsynaptic receptor loss. Increasing presynaptic ACh release beyond normal does provide some additional benefit in MG by raising the end-plate potential slightly above its already-reduced amplitude, and pyridostigmine exploits this principle. However, the additional benefit from amifampridine's presynaptic mechanism in MG is modest compared with its dramatic effect in LEMS, where it corrects the primary pathological deficit. Option D invents a presynaptic autoreceptor antagonism mechanism that does not describe amifampridine's known pharmacology.
16. The oncology and neurology teams must now coordinate a treatment plan that addresses both the SCLC and the paraneoplastic LEMS. The patient asks whether treating the cancer will affect his weakness and whether the LEMS requires its own specific treatment beyond amifampridine. Which of the following most accurately describes the integrated oncological and immunological treatment strategy for paraneoplastic LEMS associated with SCLC?
ANSWER: E
Rationale:
Paraneoplastic LEMS is driven by the immune system's response to P/Q-type VGCC antigens expressed on SCLC cells. SCLC arises from neuroendocrine precursor cells and expresses a range of neuronal proteins including P/Q-type VGCCs as part of their neuroendocrine phenotype. When the immune system generates antibodies against tumor-expressed VGCCs, these antibodies cross-react with identical channels in presynaptic motor nerve terminals and autonomic nerve endings, producing the LEMS syndrome. The tumor is therefore the antigenic source driving the autoimmune response, and treating the tumor is the most causally directed therapy for paraneoplastic LEMS. Platinum-based chemotherapy with etoposide (cisplatin or carboplatin plus etoposide) is the standard first-line regimen for extensive-stage SCLC and frequently produces objective tumor responses in 60–80% of patients. In responders, tumor shrinkage reduces the VGCC antigen load, and autoantibody titers may fall over subsequent weeks to months. Neurological improvement tracks tumor response in many patients, though the degree and speed of recovery are variable and complete LEMS resolution is uncommon. Amifampridine continues to provide symptomatic benefit during this period and should not be discontinued simply because oncological treatment has begun. For patients with severe LEMS-related weakness, significant autonomic dysfunction, or insufficient neurological improvement despite oncological response, immunotherapy is indicated. Options include intravenous immunoglobulin (IVIG), plasma exchange (plasmapheresis), corticosteroids, and steroid-sparing immunosuppressants such as azathioprine or mycophenolate mofetil. IVIG and plasma exchange provide relatively rapid but transient benefit by reducing circulating autoantibody levels, while corticosteroids and steroid-sparing agents provide slower but more sustained immunosuppression. The choice among these depends on severity of weakness, pace of SCLC treatment response, and the patient's overall performance status.